Serotonin 4 receptor agonist shows promise in preventing depression

Psilocybin shows mixed results for patients with treatment‐resistant depression
Pubblicazione: (2026)

Ketamine‐assisted ECT promising for depression; concerns around cognition remain
Pubblicazione: (2024)

Ketamine shows long‐term benefit in patients with treatment‐resistant depression
Pubblicazione: (2026)

Study of young psychiatric patients shows potential preventive benefit of doxycycline
Pubblicazione: (2026)

The demise of metformin and the rise of the GLP‐1 agonists
di: Lawrence H. Price
Pubblicazione: (2026)

Review finds VMAT‐2 inhibitors promising for treatment of psychosis
Pubblicazione: (2024)

Patients with COPD show risk of worsening from gabapentinoids
Pubblicazione: (2024)

LAI antipsychotics show effective results in comparative analysis
Pubblicazione: (2024)

Depression study shows influence of patients' treatment expectancies
Pubblicazione: (2025)

Pharmacological treatments for psychotic depression
di: Y. W. Francis Lam
Pubblicazione: (2024)

Antimicrobial exposure and risk of depression
di: Y. W. Francis Lam
Pubblicazione: (2025)

LAI paliperidone shows favorable long‐term results in schizophrenia
Pubblicazione: (2024)

Xanomeline‐trospium combination shows strong results in schizophrenia trial
Pubblicazione: (2024)

Review: Haloperidol, fluphenazine, clozapine show poor results on cognition
Pubblicazione: (2024)

Esketamine's effects in combination with SSRI vs. SNRI show differences
Pubblicazione: (2025)

Semaglutide shows favorable safety profile in patients receiving clozapine
Pubblicazione: (2025)

Study shows improved schizophrenia negative symptoms with xanomeline‐trospium
Pubblicazione: (2025)

Psilocybin‐assisted therapy shows range of benefits in cancer patients
Pubblicazione: (2025)

Fremanezumab effective for comorbid migraine and depression
Pubblicazione: (2025)

Second Phase 3 trial shows benefit of xanomeline‐trospium in schizophrenia
Pubblicazione: (2024)

Trial shows safety of switch to xanomeline‐trospium combination in stable patients
Pubblicazione: (2026)

Review shows cannabinoids have small effect on chronic pain symptoms
Pubblicazione: (2026)

Olanzapine plus samidorphan shows long‐term safety in patients with schizophrenia
Pubblicazione: (2025)

Postpartum use of dexmedetomidine reduces incidence of depression
Pubblicazione: (2024)

Adjunctive aticaprant reduces symptoms in patients with depression
Pubblicazione: (2024)

Esketamine monotherapy efficacious in treatment‐resistant depression
Pubblicazione: (2025)

Pharmacogenomic testing influenced prescribing in patients with depression
Pubblicazione: (2025)

Lumateperone effective as adjunctive therapy in patients with depression
Pubblicazione: (2025)

Postpartum hormonal contraceptives increase risk of depression
Pubblicazione: (2025)

Fast‐acting psychedelic shows antidepressant effects in Phase 2A trial
Pubblicazione: (2025)

Antidepressants for bipolar depression do not increase risk of mania
Pubblicazione: (2024)

Mixed results for esmethadone in Phase 3 depression trial
Pubblicazione: (2024)

Oral formulation of ketamine effective for treatment‐resistant depression
Pubblicazione: (2024)

Gepirone ER not linked to sexual dysfunction in patients with depression
Pubblicazione: (2024)

Study finds association between levonorgestrel exposure, depression
Pubblicazione: (2024)

Control group improvement lower in psilocybin trials for depression
Pubblicazione: (2025)